CyFlow™ CD16 FITC
| Alternative Name: | FcγRIII |
| Antibody: | Yes |
| Antigen: | CD16 |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | MEM-154 |
| Emission Maximum: | 518 nm |
| Excitation Maximum: | 490 to 495 nm |
| Field of Interest: | Immunophenotyping |
| Format/Fluorochrome: | FITC |
| Isotype: | IgG1 |
| Laser: | Blue |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | BB250643 |
For Research Use Only
| Quantity | 100 tests |
| Volume | 2.0 mL |
| Immunogen | Human granulocytes |
| Background Information | CD16 (FcγRIII) is a 50-65 kDa glycoprotein serving as a low affinity IgG receptor. Human FcγRIII is expressed in two forms - FcγRIIIA and FcγRIIIB. FcγRIIIA is a transmembrane protein of monocytes, macrophages, NK cells and a subset of T cells. It is associated with FcεRI-γ subunit and is responsible for antibody-dependent NK cell cytotoxicity. Mast cell FcγRIIIA is associated, moreover, with FcεRI-β subunit. Besides IgG, FcγRIIIA can be triggered also by oligomeric IgE. FcγRIIIB is a GPI-linked monomeric receptor expressed on neutrophils and is involved in their activation and induction of a proadhesive phenotype. |
| Usage | The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests. |
| Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J Clin Pathol. 1993 Apr; 46(4):334‑6. < PMID: 7684403 > | Gessner JE, Grussenmeyer T, Kolanus W, Schmidt RE: The human low affinity immunoglobulin G Fc receptor III‑A and III‑B genes: Molecular characterization of the promoter regions. J Biol Chem. 1995 Jan 20; 270(3):1350‑61. < PMID: 7836402 > | de Haas M, Koene HR, Kleijer M, de Vries E, Simsek S, van Tol MJ, Roos D, von dem Borne AE: A triallelic Fc gamma receptor type IIIA polymorphism influences the binding ofhuman IgG by NK cell Fc gamma RIIIa. J Immunol. 1996 Apr 15; 156(8):2948‑55. < PMID: 8609432 > | Tamm A, Schmidt RE: The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies: Implications for ligand binding. J Immunol. 1996 Aug 15; 157(4):1576‑81. < PMID: 8759741 > | Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M: Fc gammaRIIIa‑158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa‑48L/R/H phenotype. Blood. 1997 Aug 1; 90(3):1109‑14. < PMID: 9242542 > | Kocher M, Siegel ME, Edberg JC, Kimberly RP: Cross‑linking of Fc gamma receptor IIa and Fc gamma receptor IIIb induces different proadhesive phenotypes on human neutrophils. J Immunol. 1997 Oct 15; 159(8):3940‑8. < PMID: 9378982 > | Arase N, Arase H, Hirano S, Yokosuka T, Sakurai D, Saito T: IgE‑mediated activation of NK cells through Fc gamma RIII. J Immunol. 2003 Mar 15; 170(6):3054‑8. < PMID: 12626560 > | Gasdaska JR, Sherwood S, Regan JT, Dickey LF: An afucosylated anti‑CD20 monoclonal antibody with greater antibody‑dependent cellular cytotoxicity and B‑cell depletion and lower complement‑dependent cytotoxicity than rituximab. Mol Immunol. 2012 Mar; 50(3):134‑41. < PMID: 22305040 > | Ohradanova‐Repic A, Machacek C, Charvet C, Lager F, Le Roux D, Platzer R, Leksa V, Mitulovic G, Burkard TR, Zlabinger GJ, Fischer MB, Feuillet V, Renault G, Blüml S, Benko M, Suchanek M, Huppa JB, Matsuyama T, Cavaco‐Paulo A, Bismuth G, Stockinger H: Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances. FrontImmunol. 2018 Apr 27; 9:852. < PMID: 29780382 >